We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 2

1.
Figure 1

Figure 1. From: Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Progression-free survival. PFS by cohort (A) and of patients with SLL/CLL (B).

Jonathan W. Friedberg, et al. Blood. 2010 April 1;115(13):2578-2585.
2.
Figure 2

Figure 2. From: Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Waterfall plot of best responses in evaluable patients observed by cohort in the phase 2 study. Six subjects had greater than 100% increase in size of lesions; these values are listed at 100% for display purposes. Seventeen patients are not included because of early termination of drug because of toxicity or disease progression and no formal postscreening assessment.

Jonathan W. Friedberg, et al. Blood. 2010 April 1;115(13):2578-2585.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk